Zevra is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring lifechanging therapeutics to people living with rare diseases
Xylem Lab Solutions
Lab Solutions, one of the three foundational business units of Xylem Analytics, delivers a powerful portfolio of trusted analytical techniques designed to meet your most demanding laboratory challenges. With seven core brands and over a dozen testing solutions, our tools support four essential market segments: Food & Beverages, Pharmaceuticals & Life Sciences, Environmental & Municipal, and Chemical & Energy. You may wonder how one team can cover so much ground—the answer is experience. With a combined 400+ years of product development and customer support expertise, our specialists make it easy to implement tailored solutions that streamline workflows and deliver reliable results. From spectrophotometry to electrochemistry, the technologies we offer are the very same that sit side-by-side on your lab bench. Our unified platform brings them together—a state-of-the-art, ready-to-use analytical portfolio built with your lab in mind. Whatever your market, Lab Solutions is here to support you with trusted data, proven performance, and expert guidance. Let us help solve your workflow challenges—visit us today to learn how. | Xylem Lab Solutions represents the brands our customers know and love: Bellingham + Stanley, OI Analytical, YSI and Gerhardt. Xylem Lab Solutions serves as a one stop shop for every lab, making it easy for our customers to find the products and the expertise they trust. We’re committed to meeting our partners where they are, and we are proud to offer reliable lab equipment and technologies to help with any analysis– big or small.
Xcelerated Recovery®
Xcelerated Recovery® is a physician-founded perioperative nutrition company focused on improving surgical outcomes through targeted metabolic optimization. Our evidence-based formulations address muscle loss, wound healing, and infection risk, integrating seamlessly into perioperative protocols to support recovery and enhance patient function following orthopedic procedures.
X-Chem, Inc.
X-Chem is redefining small molecule drug discovery through a powerful combination of computational sciences, discovery chemistry and data-driven insight. As the pioneer and global leader in DNA-encoded library (DEL) technology, X-Chem provides the foundation for smarter hit identification, accelerated lead progression and greater confidence in early discovery. X-Chem partners globally to turn complex discovery challenges into actionable solutions.
WuXi AppTec
WuXi AppTec offers a comprehensive platform of targeted oncology models and translational services to support cancer drug development teams within the global pharmaceutical and healthcare industry. Our services include CAR-T cell therapy, antibody-drug conjugates, CRISPR-mediated target validation, drug-resistant CDX/PDX tumor models, and discovery/clinical biomarker services. | As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”
Wuhan Healthgen Biotechnology Corp.
Wuhan Healthgen Biotechnology Corp. (Stock Code: 668765) is a molecular pharmaceutical company specializing in the development, manufacturing, and marketing of recombinant proteins. Using its proprietary OryzHiExp platform, Healthgen achieves high-yield expression of proteins and peptides in rice grains. Its flagship product, Recombinant Human Serum Albumin (OsrHSA), is a critical reagent used in cell culture, medical devices, biopharmaceutical excipients, and cosmetic additives.
Worldwide Clinical Trials
About Worldwide Clinical Trials Worldwide Clinical Trials (Worldwide) is a global CRO serving development-driven biopharmaceutical companies, with more than 4,400 professionals operating across more than 70 countries. The company delivers therapeutically dedicated expertise in neuroscience, oncology, rare disease, and internal medicine, with comprehensive support across every development phase – from early-stage and first-in-human studies through Phase III registration trials. The company’s flexible service model – spanning full-service trial management to functional service partnerships through Worldwide Flex – is powered by a people-first, partnership-driven outsourcing approach that strengthens collaboration, enhances data transparency, and supports more informed decision-making. This provides sponsors with tailored, adaptable solutions that keep pace with the evolving demands of clinical research. Learn more at www.worldwide.com
Wasatch BioLabs
Wasatch BioLabs (WBL) is an independent biotechnology company with a disruptive approach to research and diagnostics. We are an R&D and Oxford Nanopore Technologies-certified laboratory that offers DNA and RNA sequencing services to researchers and clinical service providers. WBL’s solutions span both standard Oxford Nanopore Technologies sequencing services as well as proprietary methylation sequencing services built off of WBL’s NESSI-Seq platform, that expand the capabilities of the nanopore platform. | Wasatch BioLabs, a leading NGS sequencing service provider, harnesses advanced native-read sequencing and streamlined R&D workflows—translating breakthrough discovery into real-world outcomes.